Metformin prevents metabolic side effects during systemic glucocorticoid treatment.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  European Journal of Endocrinology

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/eje-16-0653PMID 28073907
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Translating the A1C Assay into Estimated Average Glucose Values in Children with Type 1 Diabetes Mellitus

  2018cited by this paper
• A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients

  2016cited by this paper
• Impact of Glucocorticoid Excess on Glucose Tolerance: Clinical and Preclinical Evidence

  2016cited by this paper
• Prevalence of dyslipidemia in Japanese patients with rheumatoid arthritis and effects of atorvastatin treatment

  2015cited by this paper
• Metformin: from mechanisms of action to therapies.

  2014cited by this paper
• Supplemental Figure 1

  2014cited by this paper
• Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase

  2014cited by this paper
• Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.

  2014cited by this paper
• Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes.

  2014cited by this paper
• Glucocorticoid‐induced hyperglycemia (糖皮质激素诱导的高血糖)

  2014cited by this paper
• Metformin—mode of action and clinical implications for diabetes and cancer

  2014cited by this paper
• Effects of metformin hydrochloride on blood glucose and insulin responses to oral dextrose in horses.

  2013cited by this paper
• Glucocorticoid treatment impairs microvascular function in healthy men in association with its adverse effects on glucose metabolism and blood pressure: a randomised controlled trial

  2013cited by this paper
• A Review of its Pharmacological Properties and Therapeutic Use in Non-Insulin-Dependent Diabetes Mellitus

  2012cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice

  2011cited by this paper
• Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids

  2011cited by this paper
• Glucagon-Like Peptide-1 Receptor Agonist Treatment Prevents Glucocorticoid-Induced Glucose Intolerance and Islet-Cell Dysfunction in Humans

  2011cited by this paper
• Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

  2010cited by this paper
• AMPK regulates metabolic actions of glucocorticoids by phosphorylating the glucocorticoid receptor through p38 MAPK.

  2010cited by this paper
• Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein.

  2009cited by this paper
• Glucocorticoid-induced hyperglycemia.

  2009cited by this paper
• Novel insights into glucocorticoid‐mediated diabetogenic effects: towards expansion of therapeutic options?

  2009cited by this paper
• Translating the A1C Assay Into Estimated Average Glucose Values

  2008cited by this paper
• AMP‐activated protein kinase mediates glucocorticoid‐ induced metabolic changes: a novel mechanism in Cushing's syndrome

  2008cited by this paper
• Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome.

  2008cited by this paper
• The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.

  2006cited by this paper
• Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome.

  2006cited by this paper
• Glucocorticoid-Induced Diabetes Mellitus: Prevalence and Risk Factors in Primary Renal Diseases

  2006cited by this paper
• AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.

  2005cited by this paper
• Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey.

  2005cited by this paper
• The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin

  2005cited by this paper
• Inflammation, stress, and diabetes.

  2005cited by this paper
• Adrenal incidentaloma: a new cause of the metabolic syndrome?

  2003cited by this paper
• Diagnosis and complications of Cushing's syndrome: a consensus statement.

  2003cited by this paper
• Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

  2003cited by this paper
• Mechanisms involved in the side effects of glucocorticoids.

  2002cited by this paper
• Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

  2002cited by this paper
• Adrenal incidentaloma: a new cause of the metabolic syndrome?

  2002cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.

  2001cited by this paper
• Use of oral corticosteroids in the United Kingdom.

  2000cited by this paper
• Prevention of dexamethasone-induced insulin resistance by metformin.

  1998cited by this paper
• Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

  1995cited by this paper
• Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A double-blind controlled study.

  1995cited by this paper
• Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome.

  1989cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function.

  1977cited by this paper

• Metformin for Glucocorticoid-Induced Toxicity: Why Not?

  2025cites this paper
• Hyperglycemia in patients treated with immune checkpoint inhibitors: key clinical challenges and multidisciplinary consensus recommendations

  2025cites this paper
• Therapeutic impacts of oral anti-diabetic drugs on Inflammatory Bowel Disease (IBD), a comprehensive review of clinical and preclinical studies.

  2025cites this paper
• 3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2026.

  2025cites this paper
• Short-term Metformin Protects Against Glucocorticoid-Induced Toxicity in Healthy Individuals: A Randomized, Double-Blind, Placebo-Controlled Trial

  2025cites this paper
• Medical Management to Treat Chronic Non-healing Ulcers: A Case Series

  2024cites this paper
• Treatment of glucocorticoid- induced hyperglycemia in hospitalized patients - a systematic review and meta- analysis

  2024cites this paper
• Efeitos adversos da corticoterapia sistêmica crônica: o que o dermatologista deve saber

  2024cites this paper
• Current Review of Comorbidities in Chronic Rhinosinusitis

  2024cites this paper
• Immunomodulation by glucocorticoid-induced leucine zipper in macrophages: enhanced phagocytosis, protection from pyroptosis, and altered mitochondrial function

  2024cites this paper
• Glucocorticoid-Induced Hyperglycemia: A Neglected Problem

  2024cites this paper
• Steroid Induced Diabetes Mellitus

  2023cites this paper
• Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know

  2023cites this paper
• Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?

  2023cites this paper
• Metabolic Complications of Glucocorticoids - Prevention by Metformin.

  2023cites this paper
• Glucose control after glucocorticoid administration in hospitalized patients – a retrospective analysis

  2022cites this paper
• Glucocorticoid-Induced Hyperglycemia Including Dexamethasone-Associated Hyperglycemia in COVID-19 Infection: A Systematic Review

  2022cites this paper
• Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions

  2022cites this paper
• Antidiabetic activity and metabolite profiles of ascidian Halocynthia roretzi

  2022cites this paper
• The effect of metformin on glucose metabolism in patients receiving glucocorticoids.

  2022cites this paper
• Drug Induced Diabetes Mellitus in Pediatric Acute Lymphoblastic Leukemia: Approach to Diagnosis and Management

  2022cites this paper
• Glucocorticoid‐induced hyperglycaemia and diabetes: Call for action

  2022cites this paper
• Is methylprednisolone acetate-related insulin resistance preventable in cats?

  2022cites this paper
• Inhibition of glucose metabolism abrogates the effector phase of bullous pemphigoid-like epidermolysis bullosa acquisita.

  2021cites this paper
• Skin and metabolic syndrome: A review of the possible associations

  2021cites this paper
• A Practical Guide for the Management of Steroid Induced Hyperglycaemia in the Hospital

  2021cites this paper
• Coadministration of sitagliptin or metformin has no major impact on the adverse metabolic outcomes induced by dexamethasone treatment in rats.

  2021cites this paper
• Evidence-Based Management of Steroid-Induced Hyperglycemia in the Inpatient Setting

  2021cites this paper
• Metformin's effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers

  2020cites this paper
• Diabète et corticoïdes : nouveautés et aspects pratiques

  2020cites this paper
• STUDY ON KNOWLEDGE AND ATTITUDE AND PRACTICE OF COLORECTAL CANCER AMONG SHAQRA POPULATION OF SAUDI ARABIA

  2020cites this paper
• [Corticosteroid-induced diabetes: Novelties in pathophysiology and management].

  2020cites this paper
• Fixing the broken clock in adrenal disorders: focus on glucocorticoids and chronotherapy.

  2020cites this paper
• AMPKα1 is essential for Glucocorticoid Receptor triggered anti-inflammatory macrophage activation

  2020cites this paper
• Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial.

  2020cites this paper
• Insulin Resistance in Chronic Disease

  2019cites this paper
• Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion.

  2019cites this paper
• Risks and benefits of corticosteroids in arthritic diseases in the clinic.

  2019cites this paper
• Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review.

  2018cites this paper
• Management of Glucocorticoid‐Induced Diabetes and/or Hyperglycemia

  2018cites this paper
• Prevention of Elevation in Plasma Triacylglycerol with High-Dose Bezafibrate Treatment Abolishes Insulin Resistance and Attenuates Glucose Intolerance Induced by Short-Term Treatment with Dexamethasone in Rats

  2018cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia

  2018cites this paper
• MANAGEMENT OF ENDOCRINE DISEASE: Critical review of the evidence underlying management of glucocorticoid-induced hyperglycaemia.

  2018cites this paper
• Optimizing the Treatment of Steroid-Induced Hyperglycemia

  2018cites this paper
• Resveratrol Attenuates Microglial Activation via SIRT1-SOCS1 Pathway

  2017cites this paper
• Therapy: Metformin reduces adverse effects of glucocorticoid treatment

  2017cites this paper
• Glucocorticoid-Induced Diabetes Mellitus: An Important but Overlooked Problem

  2017cites this paper
• Anais Brasileiros de Dermatologia

  2004cites this paper